Isorhamnetin (Iso) exhibits antitumor effects in promyelotic leukemia and lung cancers. However, its effect in liver cancer is not clear. This study explored the effects of Iso in human liver cancer cells and profiled the differential proteins upon Iso treatment, which contributes to a better understanding of its anticancer mechanisms. Stable isotope labeling with amino acids in cell culture-mass spectrometry: ESI-Iontrap (SILAC-MS) was used to study the differentially proteomic profile of Iso-treated HepG2 cells. Iso inhibits HepG2 cell proliferation in a dose-dependent manner. A total of 84 proteins are identified, among which 7 proteins were up-regulated while 77 proteins were down-regulated. Iso inhibits HepG2 cell proliferation by the induction of apoptosis and the inhibition of protein synthesis of human liver cancer cell.
Key words: Isorhamnetin, Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC), differential proteomic profile, HepG2 cells.
Copyright © 2018 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0